You're one step closer to unlocking our suite of comprehensive and robust tools.
Fill out the form so we can connect you to the right person.
If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.
Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.
At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.
IntelGenx prices $10M offering to fund acquisition
COVID-19 Pandemic Likely To Cause US Telemedicine Boom
Gauging Supply Chain Risk In Volatile Times
Cannabis: Hashing Out a Budding Industry
IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help
IntelGenx Technologies Corp. priced an offering of 15,873,016 units at 63 cents each to raise funds for the acquisition of a pharmaceutical consulting firm.
Each unit is made up of a common share and a warrant to purchase an additional stock for 90 cents each.
The Canadian company will use the $10 million raised to buy Laboval Inc., with the rest of the proceeds earmarked for the development of its medicine Montelukast.
The offering is expected to close around March 26.